Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2162)	11/29/2000 5:07:39 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 52153

Supposedly this is a new site (just turned on today I think) to assist in searching IP issues and information involving the UK patent office. Government sponsored. intellectual-property.gov.uk Hope this is as new to you as to me. --Wilder

To: scaram(o)uche who wrote (2162)	11/30/2000 12:18:20 AM
From: aknahow	Read Replies (1) \| Respond to of 52153

You may well be right about Gelonin. I am, also, interested in you opinion about ING-1. My point was that part of the past research expenses have been transformed into a partnership package with BAX. The research related to Neuprex now has a different kind of value than it did before any proof of interest by another company existed. Even so only the market should place a price on this "new" value. XOMA may be about to repeat the process with its Mycoprex research. To some extent it has packaged and sold some of it's management and technological skills to DNA to receive a 25% share in anti-cd11a, which it did not invent. So while XOMA may a first glance look like a company that just spent a lot in the past and has nothing to show for it it has been successful in turning these research expenditures into partnerships. Obviously approved products without partners would have produced more value for shareholders. Without the help of any assigned value by accounts the market has repriced XOMA, based in large part on the reduced risk profile related to the BAX agreement. Fund and institutional ownership is up from less than 5% to over 37%.